Alexey Zeifman

-managing SCOR L&H Ventures portfolio companies (track record: 2 exits, 1 investment) -leading DD and structuring new investments in HealthTech and InsurTech ares -scouting for new opportunities in HealthTech and InsurTech space

• made several global (US, UK, Russia) investments happen by leading scouting and DD process (incl. investment in US Company Bonti Therapeutics Inc., that was acquired by Allegran for $200M+) • strategized the investment portfolio of the fund by balancing risks, returns and investment horizon • de-risked investments by structuring the deals and setting milestones • recruited, coached and lead a team of Analysts (all with PhD degrees)

• brought to consideration >100 investment opportunities from conferences (BIO, JPM etc), scientific publications, network • revealed risks and opportunities for >500 investment projects (mostly US and European companies) from scientific, market, IP and financial perspectives • persuaded investment committee by making concise presentations of business cases and performing fi- nancial modelling (DCF, NPV)

Postdoc in computational chemistry • proposed structures of >100 novel small molecule GPCR ligands by applying molecular modeling (mo- lecular docking & molecular dynamics) for several projects: o functionally selective dopamine D2 ligands (publication in ACS Chem Biol) o dual targeting inhibitors for Parkinson Disease (publication in J Med Chem) • streamlined internal drug discovery process

• constructed business cases for investors by selecting new areas of development in drug discovery space • brought the novel oncology drug candidate PF-114 from idea to clinical trials stage through managing of the R&D process • secured robust and on-time preclinical results compliant with ICH, OECD and Russian non-clinical pharmacology guidelines by managing the team of medicinal chemists, pharmacologists and CROs • secured IP position of the company

Rational design of novel Syk-kinase inhibitors

Diploma with Honors, GPA 4.9/5.0